학술논문
ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial
Document Type
Article
Author
Source
In: Journal of Allergy and Clinical Immunology: Global . (Journal of Allergy and Clinical Immunology: Global, November 2023, 2(4))
Subject
Language
English
ISSN
27728293